<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692051</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KAL-BTC-03</org_study_id>
    <nct_id>NCT04692051</nct_id>
  </id_info>
  <brief_title>A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer</brief_title>
  <official_title>A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs&#xD;
      Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>PFS is defined as time from the start of treatment to progression of disease or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The rate of participants that achieve either a complete response (CR) or a partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall survival is defined as time from the start of treatment until death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to progress is defined as time from randomized grouping to objective progression of tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel + Cisplatin</intervention_name>
    <description>Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.</description>
    <arm_group_label>Nab-paclitaxel + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Cisplatin</intervention_name>
    <description>Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.</description>
    <arm_group_label>Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 70 years;&#xD;
&#xD;
          2. Diagnosis of unresectable or recurrent or metastatic biliary tract cancer (Ampulla of&#xD;
             Vater, gallbladder, intra or extra-hepatic biliary ducts);&#xD;
&#xD;
          3. Adequate bone marrow, liver and kidney function: absdute neutrophil count (ANC) ≥ 1.5&#xD;
             x 10^9/L, platelet count (PLT) ≥75 x 10^9/L, hemoglobin (HB) ≥ 75 g/L, White blood&#xD;
             cell(WBC) ≥ 3.0 x 10^9/L, no bleeding symptoms or bleeding tendency; Total bilirubin&#xD;
             (TBIL) ≤ 3 x upper limit of normal range (ULN), alanine glutamate transaminase (ALT)&#xD;
             and glutamate transaminase (AST) ≤ 5 x upper limit of normal range (ULN);&#xD;
             creatinine(Cr) ≤ 1.5 x upper limit of normal range(ULN) or creatinine clearance&#xD;
             rate（CCR）≥ 45ml/min;&#xD;
&#xD;
          4. At least one measurable lesion;&#xD;
&#xD;
          5. Karnofsky Performance Status(KPS) ≥ 70;&#xD;
&#xD;
          6. Estimated life expectancy of at least 3 months;&#xD;
&#xD;
          7. Resolution of all acute clinical toxic effects of any prior treatment to grade ≤ 1,&#xD;
             with the exception of alopecia;&#xD;
&#xD;
          8. Be able to understand and willingness to sign IRB-approved informed consent; (If the&#xD;
             patient cannot sign the informed consent due to consciousness disorder, upper limbs&#xD;
             paralysis or inability to write, the legal representative shall sign the informed&#xD;
             consent on behalf of the patient).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing uncontrolled infections, or have received systemic antibiotic therapy within&#xD;
             72 hours prior to registration;&#xD;
&#xD;
          2. Myeloproliferative disorder or any other hematopoietic function disorder;&#xD;
&#xD;
          3. Have an untreated second malignancy or brain metastasis;&#xD;
&#xD;
          4. Allergic to the chemotherapy drugs of this protocol;&#xD;
&#xD;
          5. Unable to cooperate due to neurologic diseases or psychiatric illness;&#xD;
&#xD;
          6. Pregnant or lactating female patients; Women of child-bearing age who refuse to accept&#xD;
             contraceptive measures;&#xD;
&#xD;
          7. Have other significant medical illness, for example,active tuberculosis, active&#xD;
             pneumonia, uncorrected electrolyte disturbance, uncontrolled tumor associated pain,&#xD;
             uncontrolled hydrothorax or seroperitoneum and so on;&#xD;
&#xD;
          8. Patients need to receive other antitumor therapy at the same time;&#xD;
&#xD;
          9. Have received any other experimental treatment or participated in another&#xD;
             interventional clinical trial within 30 days prior to registration;&#xD;
&#xD;
         10. Any other situation that the researcher considered patients are unsuitable for the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liang Zhuang, professor</last_name>
    <phone>+8613006325115</phone>
    <email>mrzhuangliang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Zhuang, professor</last_name>
      <phone>+8613006325115</phone>
      <email>mrzhuangliang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Head of the cancer center</investigator_title>
  </responsible_party>
  <keyword>Nab-paclitaxel + Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

